$BRTX
BioRestorative Therapies, Inc. Stock $brtx

$brtx Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000114420414030532 Filed on May 14, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q1
Revenue	$175.9K	$375.00	$1.130K
YoY Change	41297.88%	-66.81%
Cost Of Revenue	$42.37K	$60.00	$162.00
YoY Change	117583.33%	-62.96%
Gross Profit	$133.6K	$315.00	$968.00
YoY Change	34238.05%	-67.46%
Gross Profit Margin	75.92%	84.0%	85.66%
Selling, General & Admin	$1.120M	$930.0K
YoY Change
% of Gross Profit	838.48%	295238.1%
Research & Development	$293.3K	$493.7K	$400.4K
YoY Change	-21.34%	23.3%	19433.76%
% of Gross Profit	219.6%	156743.17%	41367.98%
Depreciation & Amortization	$20.00K	$25.52K	$26.74K
YoY Change		-4.56%	2.65%
% of Gross Profit	14.97%	8100.63%	2761.88%
Operating Expenses	$1.415M	$1.429M	$1.301M
YoY Change	26.99%	9.86%	-1.79%
Operating Profit	-$1.281M	-$1.428M	-$1.300M
YoY Change	15.05%	9.91%	-1.86%
Interest Expense	$72.39K	$73.13K	$197.9K
YoY Change	125.97%	-63.04%	55.68%
% of Operating Profit
Other Income/Expense, Net	-$51.65K	-$241.3K	-$266.4K
YoY Change	-62.38%	-9.44%	56.57%
Pretax Income	-$1.330M	-$1.670M
YoY Change
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.333M	-$1.670M	-$1.566M
YoY Change	6.55%	6.62%	4.79%
Net Earnings / Revenue	-757.72%	-445246.93%	-138583.89%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.167M	-$1.653M
COMMON SHARES
Basic Shares Outstanding	22.20M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$60.00K	$110.0K
YoY Change
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets	$20.00K	$10.00K
YoY Change
Inventory	$20.00K	$17.90K
Prepaid Expenses
Receivables	$0.00	$0.00
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$100.0K	$137.3K
YoY Change	51.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$20.00K	$25.52K
YoY Change	-51.47%
Goodwill
YoY Change
Intangibles		$1.090M
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.090M	$1.116M
YoY Change	-7.91%
TOTAL ASSETS
Total Short-Term Assets	$100.0K	$137.3K
Total Long-Term Assets	$1.090M	$1.116M
Total Assets	$1.190M	$1.253M
YoY Change	-4.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$890.0K	$1.203M
YoY Change	-11.27%
Accrued Expenses	$1.230M	$1.287M
YoY Change	-10.34%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.910M	$5.190M
YoY Change
Total Short-Term Liabilities	$8.260M	$7.927M
YoY Change	146.27%
LONG-TERM LIABILITIES
Long-Term Debt	$80.00K	$280.0K
YoY Change
Other Long-Term Liabilities	$0.00	$30.00K
YoY Change
Total Long-Term Liabilities	$80.00K	$310.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.260M	$7.927M
Total Long-Term Liabilities	$80.00K	$310.0K
Total Liabilities	$8.330M	$8.236M
YoY Change	19.25%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock		$22.39K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)		$32.00K
YoY Change
Treasury Stock Shares	558.6K shares	558.6K shares
Shareholders Equity	-$7.150M	-$6.983M
YoY Change
Total Liabilities & Shareholders Equity	$1.190M	$1.253M
YoY Change	-4.79%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$1.333M	-$1.670M	-$1.566M
YoY Change	6.55%	6.62%	4.79%
Depreciation, Depletion And Amortization	$20.00K	$25.52K	$26.74K
YoY Change		-4.56%	2.65%
Cash From Operating Activities	-$950.0K	-$806.7K	-$771.8K
YoY Change		4.53%	95.93%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$980.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	900.0K	$715.0K	$1.270M
YoY Change		-43.7%	290.17%
NET CHANGE
Cash From Operating Activities	-950.0K	-$806.7K	-$771.8K
Cash From Investing Activities	0.000	$980.00	$0.00
Cash From Financing Activities	900.0K	$715.0K	$1.270M
Net Change In Cash	-50.00K	-$90.74K	$498.2K
YoY Change		-118.21%	-828.46%
FREE CASH FLOW
Cash From Operating Activities	-$950.0K	-$806.7K	-$771.8K
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$950.0K	-$806.7K	-$771.8K
YoY Change		4.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Reclassifications</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Certain prior period amounts have been reclassified for comparative purposes to conform to the fiscal 2014 presentation. These reclassifications have no impact on the previously reported net loss.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1286825	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1176662	USD
CY2014Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	97139	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	65909	USD
CY2014Q1	us-gaap	Notes Payable Current NotesPayableCurrent	5189589	USD
CY2014Q1	us-gaap	Cash Cash	110360	USD
CY2013Q4	us-gaap	Cash Cash	201098	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	17904	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	17965	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9053	USD
CY2013Q4	us-gaap	Notes Payable Current NotesPayableCurrent	4990009	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7926643	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7502550	USD
CY2014Q1	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	34373	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	41434	USD
CY2014Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	275000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20739	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	137317	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	239802	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25515	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35568	USD
CY2014Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1090092	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1107545	USD
CY2014Q1	us-gaap	Assets Assets	1252924	USD
CY2013Q4	us-gaap	Assets Assets	1382915	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1203090	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1269970	USD
CY2013Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	524000	USD
CY2014Q1	us-gaap	Liabilities Liabilities	8236016	USD
CY2013Q4	us-gaap	Liabilities Liabilities	8067984	USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	22392	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	19633	USD
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	14508606	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	13139712	USD
CY2014Q1	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	21482090	USD
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	19812414	USD
CY2014Q1	us-gaap	Treasury Stock Value TreasuryStockValue	32000	USD
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	32000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	-6983092	USD
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22391635	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21833014	shares
CY2014Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	558621	shares
CY2014Q1	brtx	Credit Card Payable Current CreditCardPayableCurrent	5425	USD
CY2013Q4	brtx	Credit Card Payable Current CreditCardPayableCurrent	6000	USD
CY2014Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	677499	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	672535	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-6685069	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1252924	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1382915	USD
CY2014Q1	brtx	Debt Instrument Outstanding Face Amount Percentage DebtInstrumentOutstandingFaceAmountPercentage	0.71	pure
CY2014Q1	brtx	Debt Instrument Unamortized Debt Discount Current Portion DebtInstrumentUnamortizedDebtDiscountCurrentPortion	140911	USD
CY2013Q4	brtx	Debt Instrument Unamortized Debt Discount Current Portion DebtInstrumentUnamortizedDebtDiscountCurrentPortion	237381	USD
CY2014Q1	brtx	Debt Instrument Unamortized Debt Discount Noncurrent Portion DebtInstrumentUnamortizedDebtDiscountNoncurrentPortion	0	USD
CY2013Q4	brtx	Debt Instrument Unamortized Debt Discount Noncurrent Portion DebtInstrumentUnamortizedDebtDiscountNoncurrentPortion	3110	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19633173	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19074552	shares
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	558621	shares
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8295800	shares
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14627766	shares
CY2013Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	59940	USD
CY2014Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	603901	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	495817	USD
CY2014Q1	us-gaap	Accrued Rent Current AccruedRentCurrent	0	USD
CY2013Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	2310	USD
CY2014Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	30000	USD
CY2014Q1	brtx	Common Stock Aggregate Grant Date Fair Value CommonStockAggregateGrantDateFairValue	330436	USD
CY2014Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	5000	USD
CY2014Q1	brtx	Exchanges For Equity ExchangesForEquity	-274000	USD
CY2014Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	25000	USD
CY2014Q1	brtx	Set Up Of Debt Discount SetUpOfDebtDiscount	-5000	USD
CY2014Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	98505	USD
CY2014Q1	brtx	Accretion Of Interest Expense AccretionOfInterestExpense	11075	USD
CY2013Q1	us-gaap	Revenues Revenues	1130	USD
CY2014Q1	us-gaap	Revenues Revenues	375	USD
	us-gaap	Revenues Revenues	17644	USD
CY2013Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	162	USD
CY2014Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	60	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1575	USD
CY2013Q1	us-gaap	Gross Profit GrossProfit	968	USD
CY2014Q1	us-gaap	Gross Profit GrossProfit	315	USD
	us-gaap	Gross Profit GrossProfit	16069	USD
CY2013Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	29881	USD
CY2014Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	31794	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	586543	USD
CY2013Q1	us-gaap	Professional Fees ProfessionalFees	230116	USD
CY2014Q1	us-gaap	Professional Fees ProfessionalFees	267198	USD
	us-gaap	Professional Fees ProfessionalFees	5000136	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	400442	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	493741	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3057692	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	640110	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	636000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9910011	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	1300549	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	1428733	USD
	us-gaap	Operating Expenses OperatingExpenses	18554382	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1299581	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1428418	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18538313	USD
CY2013Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2014Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	11457	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	197868	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	73131	USD
	us-gaap	Interest Expense InterestExpense	1324723	USD
CY2013Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	61349	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1389928	USD
CY2013Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7200	USD
CY2014Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-49094	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-126002	USD
CY2013Q1	brtx	Warrant Modification Expense WarrantModificationExpense	0	USD
CY2014Q1	brtx	Warrant Modification Expense WarrantModificationExpense	-30128	USD
	brtx	Warrant Modification Expense WarrantModificationExpense	-245040	USD
CY2013Q1	brtx	Gain Loss Related To Settlement Of Note And Payables GainLossRelatedToSettlementOfNoteAndPayables	0	USD
CY2014Q1	brtx	Gain Loss Related To Settlement Of Note And Payables GainLossRelatedToSettlementOfNoteAndPayables	9600	USD
	brtx	Gain Loss Related To Settlement Of Note And Payables GainLossRelatedToSettlementOfNoteAndPayables	120095	USD
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-266417	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-241258	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2954141	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-1565998	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-1669676	USD
	us-gaap	Net Income Loss NetIncomeLoss	-21492454	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.77
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.23
CY2014Q1	brtx	Warrant Modification Charge WarrantModificationCharge	30128	USD
CY2014Q1	brtx	Share Based Compensation Exercise Price Range Number Of Outstanding Warrants ShareBasedCompensationExercisePriceRangeNumberOfOutstandingWarrants	5325751	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2740000	shares
CY2014Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7783000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5147167	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.03
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.65
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15307958	shares
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20237689	shares
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1368651	shares
CY2014Q1	brtx	Warrant To Purchase Common Stock Issued In Period WarrantToPurchaseCommonStockIssuedInPeriod	266667	shares
CY2014Q1	brtx	Estimated Forfeitures Related To Option Grants Annual Rate EstimatedForfeituresRelatedToOptionGrantsAnnualRate	0	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	831669	shares
CY2014Q1	brtx	Share Based Compensations Exercise Price Range Exercisable Warrant Weighted Average Remaining Contractual Term ShareBasedCompensationsExercisePriceRangeExercisableWarrantWeightedAverageRemainingContractualTerm	P2Y9M18D
CY2014Q1	brtx	Share Based Compensation Exercise Price Range Number Of Exercisable Warrants ShareBasedCompensationExercisePriceRangeNumberOfExercisableWarrants	4625751	shares
CY2014Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10000	USD
CY2014Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	80000	USD
CY2014Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	359428	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	182607	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	305702	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2724366	USD
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	481970	USD
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M18D
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5043000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.90
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.89
CY2014Q1	brtx	Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M24D
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2014Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	7783000	shares
CY2014Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2014Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	5147167	shares
CY2013Q4	brtx	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNumber	0	shares
CY2014Q1	brtx	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGranted	21691	shares
CY2014Q1	brtx	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVested	-21691	shares
CY2014Q1	brtx	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsForfeited	0	shares
CY2014Q1	brtx	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNumber	0	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.65
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.65
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0
CY2013Q4	brtx	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue	0	USD
CY2014Q1	brtx	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue	14071	USD
CY2014Q1	brtx	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue	-14071	USD
CY2014Q1	brtx	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresGrantDateFairValue	0	USD
CY2014Q1	brtx	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue	0	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26735	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	25517	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	365914	USD
CY2013Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2014Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1009	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-22623	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	255530	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	373499	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5316543	USD
CY2013Q1	brtx	Warrant Issued In Connection With Note Payable WarrantIssuedInConnectionWithNotePayable	0	USD
CY2014Q1	brtx	Warrant Issued In Connection With Note Payable WarrantIssuedInConnectionWithNotePayable	0	USD
	brtx	Warrant Issued In Connection With Note Payable WarrantIssuedInConnectionWithNotePayable	9400	USD
CY2013Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1338	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-61	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	17904	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	35000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-11686	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9053	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1840	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-59380	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1157079	USD
CY2013Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	477909	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	192429	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2450568	USD
CY2013Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	794225	USD
CY2014Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	862948	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	11086045	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-771773	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-806728	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10406409	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	176936	USD
CY2013Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2014Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	980	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	32980	USD
CY2013Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2014Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1003676	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	980	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1147632	USD
CY2013Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	450000	USD
CY2014Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	140000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	7433139	USD
CY2013Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	590722	USD
CY2014Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	293343	USD
CY2013Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	59940	USD
CY2014Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	24990	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	293343	USD
CY2013Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	587684	USD
CY2013Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2014Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	32000	USD
CY2014Q1	brtx	Property Plant And Equipment Additions In Accounts Payable PropertyPlantAndEquipmentAdditionsInAccountsPayable	0	USD
	brtx	Property Plant And Equipment Additions In Accounts Payable PropertyPlantAndEquipmentAdditionsInAccountsPayable	60000	USD
CY2014Q1	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-90738	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	110360	USD
CY2012Q4	us-gaap	Cash Cash	363	USD
CY2008Q4	us-gaap	Cash Cash	0	USD
CY2013Q1	brtx	Amounts Payable Related To Common Stock Repurchased AmountsPayableRelatedToCommonStockRepurchased	0	USD
CY2014Q1	brtx	Amounts Payable Related To Common Stock Repurchased AmountsPayableRelatedToCommonStockRepurchased	0	USD
	brtx	Amounts Payable Related To Common Stock Repurchased AmountsPayableRelatedToCommonStockRepurchased	7000	USD
CY2013Q1	brtx	Contingent Common Stock Issued ContingentCommonStockIssued	0	USD
CY2014Q1	brtx	Contingent Common Stock Issued ContingentCommonStockIssued	0	USD
	brtx	Contingent Common Stock Issued ContingentCommonStockIssued	12577	USD
CY2013Q1	brtx	Supplemental Reduction Of Fixed Assets Based On Write Off Of Capital Lease SupplementalReductionOfFixedAssetsBasedOnWriteOffOfCapitalLease	0	USD
CY2014Q1	brtx	Supplemental Reduction Of Fixed Assets Based On Write Off Of Capital Lease SupplementalReductionOfFixedAssetsBasedOnWriteOffOfCapitalLease	0	USD
CY2013Q1	brtx	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	820000	USD
CY2014Q1	brtx	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	545000	USD
	brtx	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	4266300	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1270000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	715010	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11664401	USD
CY2013Q1	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	498227	USD
CY2013Q1	us-gaap	Cash Cash	498590	USD
CY2013Q1	us-gaap	Interest Paid InterestPaid	16091	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	16804	USD
	us-gaap	Interest Paid InterestPaid	680967	USD
CY2013Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
CY2014Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	291055	USD
CY2013Q1	brtx	Property Plant And Equipment Additions In Accounts Payable PropertyPlantAndEquipmentAdditionsInAccountsPayable	0	USD
	brtx	Supplemental Reduction Of Fixed Assets Based On Write Off Of Capital Lease SupplementalReductionOfFixedAssetsBasedOnWriteOffOfCapitalLease	226043	USD
CY2013Q1	brtx	Common Stock And Warrants Issued To Convert Notes Payable And Accrued Interest CommonStockAndWarrantsIssuedToConvertNotesPayableAndAccruedInterest	119700	USD
CY2014Q1	brtx	Common Stock And Warrants Issued To Convert Notes Payable And Accrued Interest CommonStockAndWarrantsIssuedToConvertNotesPayableAndAccruedInterest	343026	USD
	brtx	Common Stock And Warrants Issued To Convert Notes Payable And Accrued Interest CommonStockAndWarrantsIssuedToConvertNotesPayableAndAccruedInterest	1584915	USD
CY2013Q1	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	0	USD
CY2014Q1	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	0	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	226500	USD
CY2013Q1	brtx	Reclassification Of Accrued Interest In Connection With Note Payable Issuance ReclassificationOfAccruedInterestInConnectionWithNotePayableIssuance	0	USD
CY2014Q1	brtx	Reclassification Of Accrued Interest In Connection With Note Payable Issuance ReclassificationOfAccruedInterestInConnectionWithNotePayableIssuance	0	USD
	brtx	Reclassification Of Accrued Interest In Connection With Note Payable Issuance ReclassificationOfAccruedInterestInConnectionWithNotePayableIssuance	74285	USD
CY2013Q1	brtx	Waiver Of Previously Accrued Executive Salary And Bonus WaiverOfPreviouslyAccruedExecutiveSalaryAndBonus	0	USD
CY2014Q1	brtx	Waiver Of Previously Accrued Executive Salary And Bonus WaiverOfPreviouslyAccruedExecutiveSalaryAndBonus	0	USD
	brtx	Waiver Of Previously Accrued Executive Salary And Bonus WaiverOfPreviouslyAccruedExecutiveSalaryAndBonus	565000	USD
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	dei	Trading Symbol TradingSymbol	BRTX
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22202276	shares
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	BioRestorative Therapies, Inc.
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001505497
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	150000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	150000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	150000	USD
CY2014Q1	brtx	Payments Under Research And Development Agreements PaymentsUnderResearchAndDevelopmentAgreements	25000	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	5000	shares
CY2014Q1	brtx	Stock Issued During Period Value Issued In Exchange Of Notes Payable Principal Amount StockIssuedDuringPeriodValueIssuedInExchangeOfNotesPayablePrincipalAmount	274000	USD
CY2014Q1	brtx	Stock Issued During Period Value Issued In Exchange Of Notes Payable Interest Amount StockIssuedDuringPeriodValueIssuedInExchangeOfNotesPayableInterestAmount	19932	USD
CY2014Q1	brtx	Stock Issued During Period Shares Issued In Exchange Of Notes Payable StockIssuedDuringPeriodSharesIssuedInExchangeOfNotesPayable	1101453	shares
CY2014Q1	brtx	Warrants Issued During Period Number Of Warrants WarrantsIssuedDuringPeriodNumberOfWarrants	100000	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	0.75
CY2014Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	25000	USD
CY2014Q1	brtx	Warrants Issued During Period Number Of Warrants1 WarrantsIssuedDuringPeriodNumberOfWarrants1	0.75	shares
CY2014Q1	brtx	Adjustments To Additional Paid In Capital Warrant Modification AdjustmentsToAdditionalPaidInCapitalWarrantModification	30128	USD
CY2014Q1	brtx	Debt Instrument Issue Description DebtInstrumentIssueDescription	(a) 55% of the fair value of the Companys stock or (b) $0.05 per share. The remaining $30,000 is convertible into shares of the Companys common stock at the election of the holder any time after September 10, 2014 at the lesser of (a) $0.50 per share or (b) 65% of the fair value of the Companys common stock, but with a floor of $0.05 per share.
CY2014Q1	brtx	Warrant Aggregate Grant Date Fair Value WarrantAggregateGrantDateFairValue	12590	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y
CY2014Q1	brtx	Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue	67830	USD
CY2014Q1	brtx	Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue	5860	USD
CY2013Q4	brtx	Loss Contingency Claim Of Shares LossContingencyClaimOfShares	80000	shares
CY2013Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	36000	USD
CY2014Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	11000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	344000	USD
CY2014Q2	us-gaap	Other Notes Payable OtherNotesPayable	652500	USD

Files In Submission

Name	View Source	Status
0001144204-14-030532-index-headers.html	Edgar Link	pending
0001144204-14-030532-index.html	Edgar Link	pending
0001144204-14-030532.txt	Edgar Link	pending
0001144204-14-030532-xbrl.zip	Edgar Link	pending
brtx-20140331.xml	Edgar Link	completed
brtx-20140331.xsd	Edgar Link	pending
brtx-20140331_cal.xml	Edgar Link	unprocessable
brtx-20140331_def.xml	Edgar Link	unprocessable
brtx-20140331_lab.xml	Edgar Link	unprocessable
brtx-20140331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
page1.jpg	Edgar Link	pending
page2.jpg	Edgar Link	pending
page3.jpg	Edgar Link	pending
page4.jpg	Edgar Link	pending
page5.jpg	Edgar Link	pending
page6.jpg	Edgar Link	pending
page7.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v377379_10q.htm	Edgar Link	pending
v377379_ex-32.htm	Edgar Link	pending
v377379_ex10-1.htm	Edgar Link	pending
v377379_ex10-2.htm	Edgar Link	pending
v377379_ex10-3.htm	Edgar Link	pending
v377379_ex10-4.htm	Edgar Link	pending
v377379_ex31-1.htm	Edgar Link	pending
v377379_ex31-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BRTX
BioRestorative Therapies, Inc. Stock $brtx

2014 Q2 Form 10-Q Financial Statement

#000114420414030532 Filed on May 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRTX BioRestorative Therapies, Inc. Stock $brtx

2014 Q2 Form 10-Q Financial Statement

#000114420414030532 Filed on May 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRTX
BioRestorative Therapies, Inc. Stock $brtx